New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2013
05:48 EDTCTICCell Therapeutics announces interim results from Phase 2 tosedostat trial
Cell Therapeutics announced promising interim results from an investigator-initiated Phase 2 clinical trial of tosedostat in combination with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukemia, or AML, or high-risk myelodysplastic syndrome, or MDS. Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival. Tosedostat is administered orally and has been previously shown to induce complete remissions as monotherapy in relapsed or refractory AML. John Pagel, M.D., Ph.D., Principal Investigator in the tosedostat first-line AML/MDS trial stated, "Treatment outcomes for older patients with newly diagnosed AML remain poor. This is the first time that tosedostat has been given in a front-line setting in combination with low intensity therapy. The complete response rates and median survival observed in previously untreated older patients with AML is promising and appears to be worthy of further clinical investigation."
News For CTIC From The Last 14 Days
Check below for free stories on CTIC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 19, 2014
20:10 EDTCTICCell Therapeutics in pact with DSM Fine Chemicals Austria
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use